Table 1.
Did not initiate NNRTI-based regimen N=117 n (%) | Initiated NNRTI-based regimen N=16 n (%) | p Value | |
---|---|---|---|
Age, years (median) | 10.1 | 11.8 | 0.17 |
Race/ethnicity | 0.16 | ||
White, non-Hispanic | 3 (2.6) | 2 (12.5) | |
Black, non-Hispanic | 84 (71.8) | 9 (56.3) | |
Hispanic | 27 (23.1) | 5 (31.3) | |
Other/unknown | 3 (2.6) | 0 (0) | |
Gender | 0.14 | ||
Male | 50 (42.7) | 10 (62.5) | |
Female | 67 (57.3) | 6 (37.5) | |
Mode of HIV infection | 0.62 | ||
Perinatal | 95 (81.2) | 12 (75) | |
Breastfeeding only | 1 (0.9) | 0 (0) | |
Blood transfusion, blood products only | 3 (2.6) | 0 (0) | |
Behavioral—consensual sexual activity only | 3 (2.6) | 0 (0) | |
Sexual abuse only | 2 (1.7) | 1 (6.3) | |
Other only | 2 (1.7) | 0 (0) | |
Multiple risks | 9 (7.7) | 3 (18.8) | |
Unknown transmission | 1 (0.9) | 0 (0) | |
Men who have sex with men | 1 (0.9) | 0 (0) | |
Injection drug use | 0 (0.0) | 0 (0.0) | |
Adherence after mutation detected | 0.02 | ||
No documented adherence problem | 36 (30.8) | 10 (62.5) | |
Documented adherence problem | 81 (69.2) | 6 (37.5) | |
Poor clinic attendance | 0.051 | ||
Yes | 23 (19.7) | 7 (43.8) | |
No | 94 (80.3) | 9 (56.2) | |
Immunologic stage when mutation detected | 0.12 | ||
CD4 ≥200 cells/mL (CD4% ≥14%) | 84 (80.0) | 10 (62.5) | |
CD4 <200 cells/mL (CD4% <14%) | 21 (20.0) | 6 (37.5) |
105 individuals had available CD4 testing at the time NNRTI mutation detected.